Clinical Trial Update: Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of gemcitabine hydrochloride, dasatinib, and erlotinib hydrochloride in patients with metastatic or unresectable pancre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer
• Pancreatic Carcinoma

Drugs mentioned

• DASATINIB (Dasatinib)
• Erlotinib hydrochloride (Erlotinib)
• Gemcitabine hydrochloride (Gemcitabine hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING